author-image
TEMPUS

Headaches in the health business

The Times

Where to start with Reckitt Benckiser? A bumper acquisition that seems to be taking a long time to digest and is causing hiccups in the process? Questions about sales in the United States and China? Doubts about margins and investment levels? Tribulations over bumpy product launches and factory shutdowns? Or nervousness about long-term organic growth.

At least the chief executive of the giant consumer goods group is new to the job and has several months to prepare for his big strategy day in February, time that will give him the chance to imprint his ideas on the group. Meanwhile, shares in the FTSE 100 stalwart could do with a couple of Nurofen to help to relieve the discomfort.

Reckitt Benckiser is one of the